9:00am - 5:00pm

Our Opening Hours Mon. - Fri.

1.800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

Genetically Modified T Cells in Treating Patients With Stage III-IV Non-small Cell Lung Cancer or Mesothelioma

Top West Virginia Mesothelioma Lawyer | Law Firm | Attorney | GPW > Genetically Modified T Cells in Treating Patients With Stage III-IV Non-small Cell Lung Cancer or Mesothelioma

Genetically Modified T Cells in Treating Patients With Stage III-IV Non-small Cell Lung Cancer or Mesothelioma

Estimated reading time: 1 min

Condition: Advanced Pleural Malignant Mesothelioma

Estimated Enrollment: 20

Gender: All

Min Age: 18 Years

Age Group: Adult, Older Adult

Current Status: Active, not recruiting

Study Results: No Results Available

Outcome Measures: Evidence and nature of toxicity,  Feasibility of naive T cell (TN) and central memory T cell (TCM) subsets, measured as the proportion of patients for which T cells are successfully generated and infused and whether only TN or TCM could be generated,  Persistence of transduced T cells, Frequency of transferred T cells at biopsied tumor sites between the T cell (Tn) and memory T cell (Tcm) groups

Interventions: Aldesleukin, Autologous WT1-TCRc4 Gene-transduced CD8-positive Tcm/Tn Lymphocytes

Phase:

Study Type: Interventional

Study Design: Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: None (Open Label),Primary Purpose: Treatment

Primary Completion Date: June 30, 2020

Completion Date: June 30, 2022

Last  Posted Date: June 21, 2019

Location: Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Website Link: https://ClinicalTrials.gov/show/NCT02408016

Was this article helpful?
Dislike 0